Engineering low-endotoxin lipid A in a double auxotroph Pseudomonas aeruginosa to develop safer whole-cell vaccines

UDC.coleccionInvestigación
UDC.departamentoFisioterapia, Medicina e Ciencias Biomédicas
UDC.grupoInvInvestigación en Microbiología (INIBIC)
UDC.institutoCentroINIBIC - Instituto de Investigacións Biomédicas de A Coruña
UDC.journalTitleFrontiers in Cellular and Infection Microbiology
UDC.volume16
dc.contributor.authorFuentes-Valverde, Víctor
dc.contributor.authorGarcía, Patricia
dc.contributor.authorCandela, Ana
dc.contributor.authorSantamarina-Fernández, Rebeca
dc.contributor.authorAvendaño-Ortiz, José
dc.contributor.authorMartínez-Alonso, Emma
dc.contributor.authorOviaño, Marina
dc.contributor.authorCantón, Rafael
dc.contributor.authorArenas, Jesús
dc.contributor.authorMoscoso, Miriam
dc.contributor.authorBou, Germán
dc.date.accessioned2026-08-20T10:28:43Z
dc.date.available2026-08-20T10:28:43Z
dc.date.issued2026-06-01
dc.description.abstract[Abstract] Introduction: Pseudomonas aeruginosa is a highly adaptable Gram-negative bacterium causing severe respiratory infections, particularly in vulnerable populations. The rise of antimicrobial resistance highlights the urgent need for effective vaccines. We previously developed a live-attenuated vaccine candidate, PAO1 ΔmurI Δalr ΔdadX, a genetically stable double auxotrophic strain that exhibited dose-dependent reactogenicity upon intranasal administration in mice, likely due to lipid A component of lipopolysaccharide (LPS). Methods: To reduce LPS-associated toxicity while preserving immunogenicity, we engineered novel strains by inactivating genes involved in lipid A biosynthesis (htrB1, htrB2) or modification (pagP, pagL). Lipid A structural modifications were confirmed by MALDI-TOF MS. Mutants were evaluated for Toll-like receptor 4 (TLR4) activation, virulence attenuation, and their ability to induce immune responses and protection in an acute pneumonia model. Results: All engineered strains displayed modified lipid A structures. Mutations in htrB1 and htrB2 reduced TLR4 activation and significantly attenuated virulence following intraperitoneal challenge in mice. Inactivation of pagL resulted in minimal attenuation, whereas pagP inactivation led to marked attenuation without altering TLR4 activation. In the acute pneumonia model, all mutants elicited robust systemic and mucosal immune responses, and conferred strong protection, despite transient weight loss following intranasal administration. Discussion: Targeted lipid A modification represents an effective strategy to reduce in vitro reactogenicity while preserving immunogenicity in live-attenuated P. aeruginosa vaccine candidates. Although further optimization may minimize residual in vivo effects, these findings support the potential of engineered strains as vaccine candidates for preventing respiratory infections caused by P. aeruginosa.
dc.description.sponsorshipThe author(s) declared that financial support was received for this work and/or its publication. This work was supported by a grant from the SERGAS-Galician Healthcare Service (Program “Innova Saúde”), CIBERINFEC, and the projects PI18/00501 and PI21/00704 to GB, and the project PI20/00686 to MO, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 from the Ministry of Economy and Competitiveness and the Institute of Health Carlos III. In addition, this work was supported by the Ciencia e Innovación/Agencia Española de Investigación MCIN/AEI/10.13039/501100011033 and, as appropriate, by ERDF A way of making Europe by the European Union or by the European Union Next Generation EU/PRTR (Grant agreement PID2020-114617RB-100) to JA. VF-V was funded with a predoctoral fellowship from the Conselleria de Cultura, Xunta de Galicia (IN606A-2019/012) and by the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) for a research stay (May-July 2022) at the University of Zaragoza. AC was financially supported by the Río Hortega program (ISCIII-SERGAS, CM21/00165).
dc.identifier.citationFuentes-Valverde V, García P, Candela A, Santamarina-Fernández R, Avendaño-Ortiz J, Martínez-Alonso E, Oviaño M, Cantón R, Arenas J, Moscoso M, Bou G. Engineering low-endotoxin lipid A in a double auxotroph Pseudomonas aeruginosa to develop safer whole-cell vaccines. Front Cell Infect Microbiol. 2026 Jun 1;16:1840122.
dc.identifier.doi10.3389/FCIMB.2026.1840122
dc.identifier.issn2235-2988
dc.identifier.urihttps://hdl.handle.net/2183/49059
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2013-2016/PI18%2F00501/ES/DISEÑO Y DESARROLLO DE UNA VACUNA PARA LA PREVENCION Y ERRADICACION DE LAS INFECCIONES RESPIRATORIAS AGUDAS Y CRONICAS (FIBROSIS QUISTICA) CAUSADAS POR PSEUDOMONAS AERUGINOSA/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PI21%2F00704/ES/VACUNAS AUXOTROFAS ORALES PARA LA ERRADICACION DE BACTERIAS INTESTINALES: COLONIZACIÓN INTESTINAL POR KLEBSIELLA PNEUMONIAE MULTIRRESISTENTE COMO MODELO/
dc.relation.projectIDinfo:eu-repo/grantAgreement/ISCIII/Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020/PI20%2F00686/ES/DETECCION RAPIDA DE RESISTENCIAS ANTIBIOTICAS MEDIANTE ESPECTROMETRIA DE MASAS MALDI-TOF/
dc.relation.urihttps://doi.org/10.3389/FCIMB.2026.1840122
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectPseudomonas aeruginosa
dc.subjectAuxotrophy
dc.subjectHumoral immunity
dc.subjectLipopolysaccharide
dc.subjectLive-attenuated vaccines
dc.subjectProtective efficacy
dc.titleEngineering low-endotoxin lipid A in a double auxotroph Pseudomonas aeruginosa to develop safer whole-cell vaccines
dc.typejournal article
dc.type.hasVersionVoR
dspace.entity.typePublication
relation.isAuthorOfPublication909e08d1-6ed1-4b99-9e9e-c64eb72e7dea
relation.isAuthorOfPublication.latestForDiscovery909e08d1-6ed1-4b99-9e9e-c64eb72e7dea

Files

Original bundle

Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
Fuentes_Engineering_2026.pdf
Size:
3.67 MB
Format:
Adobe Portable Document Format
Loading...
Thumbnail Image
Name:
Fuentes_Engineering_2026_Suppl.pdf
Size:
3.67 MB
Format:
Adobe Portable Document Format
Description:
Supplementary material